Percutaneous permeation of betamethasone 17-valerate incorporated in lipid nanoparticles

Journal of Pharmaceutical Sciences

Volumn 100, Issue 3, 2011, Pages 896-903

  Zhang, Jin ^a   Smith, Eric ^b  

^a University of Southern Nevada   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Drug targeting; Nanoparticles; Percutaneous; Permeability; Skin

Indexed keywords

BETAMETHASONE VALERATE; GLYCEROL STEARATE; PROPOLIS; SOLID LIPID NANOPARTICLE;

AGED; ARTICLE; CONTROLLED DRUG RELEASE; DERMIS; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG PENETRATION; EPIDERMIS; FEMALE; HUMAN; HUMAN TISSUE; LIPID COMPOSITION; NANOENCAPSULATION; PARTICLE SIZE; SKIN PENETRATION; ZETA POTENTIAL;

EID: 79251551386     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22329     Document Type: Article

References (18)

1. Schafer-Korting M, Mehnert W, Korting HC. 2007. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev 59(6):427-443.
2. DiPiro JT. 2008. Pharmacotherapy: A pathophysiologic approach. 7th ed. New York: McGraw-Hill Medical. pp xxxii, 2559.
3. Del Rosso J, Friedlander SF. 2005. Corticosteroids: Options in the era of steroid-sparing therapy. J Am Acad Dermatol 53(1 Suppl. 1):S50-S58.
4. Muller RH, Radtke M, Wissing SA. 2002. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 54(Suppl. 1): S131-S155.
5. Muller RH, Mader K, Gohla S. 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 50(1):161-177.
6. Kuchler S, Radowski MR, Blaschke T, Dathe M, Plendl J, Haag R, Schafer-Korting M, Kramer KD. 2009. Nanoparticles for skin penetration enhancement-a comparison of a dendritic core-multishell-nanotransporter and solid lipid nanoparticles. Eur J Pharm Biopharm 71(2):243-250.
7. Charman C, Williams H. 2003. The use of corticosteroids and corticosteroid phobia in atopic dermatitis. Clin Dermatol 21(3):193-200.
8. Zhang J, Fan Y, Smith E. 2009. Experimental design for the optimization of lipid nanoparticles. J Pharm Sci 98(5):1813-1819.
9. Mei Z, Chen H, Weng T, Yang Y, Yang X. 2003. Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. Eur J Pharm Biopharm 56(2):189-196.
10. Souto EB, Wissing SA, Barbosa CM, Muller RH. 2004. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 278(1):71-77.
11. Hu FQ, Hong Y, Yuan H. 2004. Preparation and characterization of solid lipid nanoparticles containing peptide. Int J Pharm 273(1-2):29-35.
12. zur Muhlen A, Schwarz C, Mehnert W. 1998. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm 45(2):149-155.
13. Kligman AM, Christophers E. 1963. Preparation of isolated sheets of human stratum corneum. Arch Dermatol 88:702-705.
14. Pefile S, Smith E, Albrecht C, Kruger P. 1998. Release of rooperol tetraacetate from topical bases: In vitro studies using silicone membrane. Int Pharm 161(2):237-243.
15. Jenning V, Gohla S. 2000. Comparison of wax and glyceride solid lipid nanoparticles (SLN). Int J Pharm 196(2):219-222.
16. Lee CK, Uchida T, Noguchi E, Kim NS, Goto S. 1993. Skin permeation enhancement of tegafur by ethanol/panasate 800 or ethanol/water binary vehicle and combined effect of fatty acids and fatty alcohols. J Pharm Sci 82(11):1155-1159.
17. Alvarez-Roman R, Naik A, Kalia YN, Guy RH, Fessi H. 2004. Skin penetration and distribution of polymeric nanoparticles. J Control Release 99(1):53-62.
18. Shim J, Seok Kang H, Park WS, Han SH, Kim J, Chang IS. 2004. Transdermal delivery of mixnoxidil with block copolymer nanoparticles. J Control Release 97(3):477-484.